Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immune Checkpoint Therapy;Adoptive Cell Therapy
Treatment anti-PD-1
Drugstatus NA
Drugbank ID NA
Checkpoints PD-1
Signature Type Gene
Signature IL12rb2
Official Symbol IL12RB2
Mode of action TRAN_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Mouse model
Description First, a six gene cluster was found to be significantly upregulated in the combination group. This includes Cd1d2, Ltf, Klra21, H60a, Tnfsf18, and Bcl6. Another cluster was found to be significantly downregulated and consists of Egr3, Cd46, Ncr1, Klra5, Ccl1, Il12rb2, and Cd59b
PMID 29339375
Title TUSC2 immunogene therapy synergizes with anti–PD-1 through enhanced proliferation and infiltration of natural killer cells in syngeneic Kras-mutant mouse lung cancer models